Denali Therapeutics Inc

DNLI03 Dec 2024
Healthcare
$24.93
+0.03 (+2.60%)
Lowest Today
$24.86
Highest Today
$25.83
Today’s Open
$24.93
Prev. Close
$25
52 Week High
$33.33
52 Week Low
$14.56
To Invest in Denali Therapeutics Inc

Denali Therapeutics Inc

Healthcare
DNLI03 Dec 2024
+0.03 (+2.60%)
1M
3M
6M
1Y
5Y
Low
$24.86
Day’s Range
High
$25.83
24.86
52 Week Low
$14.56
52-Week Range
52 Week High
$33.33
14.56
1 Day
-
1 Week
+2.01%
1 month return
-6.89%
3 month return
+2.33%
6 month return
+35.42%
1 Year return
+34.77%
3 Years return
-46.02%
5 Years return
+47.57%
10 Years return
-
Institutional Holdings
Baillie Gifford & Co Limited.
9.27
BlackRock Inc
9.15
Vanguard Group Inc
7.77
Wellington Management Company LLP
6.83
Vanguard Health Care Inv
6.11
Capital Research Global Investors
5.5
FMR Inc
5.44

Market Status

Fundamentals
Market Cap
3621.08 mln
PB Ratio
2.75
PE Ratio
0
Enterprise Value
2837.03 mln
Total Assets
1153.92 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Organisation
Denali Therapeutics Inc
Employees
390
Industry
Biotechnology
CEO
Dr. Ryan J. Watts Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step